Abstract. We present an intra-host mathematical model of malaria that describes the interaction of the immune system with the blood stage malaria merozoites. The model is modified by incorporating the effects of malaria drugs that target blood stage parasites. The optimal control represents a percentage effect of the chemotherapy of chloroquine in combination with chlorpheniramine on the reproduction of merozoites in erythrocytes. First we maximise the benefit based on the immune cells, and minimise the systemic cost based on the percentage of chemotherapies given and the population of merozoites. An objective functional to minimise merozite reproduction and treatment systemic costs is then built. The existence and uniqueness results for the optimal control are established. The optimality system is derived and the Runge-Kutta fourth order scheme is used to numerically simulate different therapy efforts. Our results indicate that highly toxic drugs with the compensation of high infection suppression have the potential of yeilding better treatment results than less toxic drugs with less infection suppression potential or high toxic drugs with less infection suppression potential. In addition, we also observed that a treatment protocol with drugs with high adverse effects and with a high potential of merozoite suppression can be beneficial to patients. However, an optimal control strategy that seeks to maximise immune cells has no potential to improve the treatment of blood stage malaria.
Introduction
Malaria remains a major public health problem in most tropical countries, particularly sub-Saharan Africa. It has been estimated that between 300 million and 500 million individuals are infected annually and between 1.5 million and 2.7 million people die of malaria every year [1] . Malaria is caused by the protozoan Plasmodium and is transmitted to humans by female Anophele mosquitoes. Of the four species of plasmodia infecting humans, P. falciparum accounts for the most severe and often potentially lethal form of malaria. Malaria parasites injected into the human host by mosquitoes initially migrate to the liver where they develop into schizonts which rapture, releasing a large number of daughter merozoites into the blood stream. There, each merozoite invades a fresh erythrocyte to renew the cycle. The erythrocyte cycle maintains infection and directly generates disease symptoms [2, 3] .
The infection of humans by malaria solicit immunity development, such that individuals that are repeatedly exposed to P. falciparum infection acquire partial immunity. Consequently, non-immune children in areas of high endemicity suffer severe malaria, while adults suffer fewer clinical malaria episodes [3] . Naturally acquired immunity is not completely understood. However, several studies [2] [3] [4] [5] [6] concluded that both cellmediated and antibody-dependent immunity are required for adequate protection. Both types of responses are critically dependent on CD4+ T cells. The two main facets of CD4+ T cells that are functionally distinguished by the cytokines they solicit, thats is, (i) Th1-type which mainly induce γ-interferon (IFN-γ), and (ii) Th2-type which induce interlukine-4 (IL-4) and IL-5. Both the Th1 and Th2 responses seem to be required to regulate the infection of humans with P. falciparum malaria. However, they need to be adequately tuned in intensity and on time [2] . It has been proposed in murine malaria that innate and adaptive responses are required for parasite elimination [5] . The difference between lethal and non-lethal is explained by the expression of cytokines stimulated by the infection, such that production of IFN-γ, IL-12 and TNF-α responses are associated with non-lethal malaria and even elimination of infection. However, overproduction of IFN-γ or TNF-α predisposes to severe pathology [4, 5, 7] .
Chloroquine (CQ) has remained the drug of choice for the chemosuppression and radical cure of malaria particularly in the tropics, primarily because it is cheap, rapidly effective and readily available [8] . However, the wide spread emergence of CQ-resistance P. falciparum strains has led to studies to counter the threat of CQ resistant strains through development of combinations of antimalarials [9, 10] , which are now recommended by world health organisation (WHO). Antimalarial combination therapy is the simultaneous use of two (sulfadoxine-pyrimethamine, sulfalene-pyrimethamine, proguanil-dapsone, etc.) or more blood schizontocidal drugs with independent modes of action. The concept is based on the potential of two or more schizontocidal drugs to improve therapeutic efficacy and delay the development of resistance to the individual components [9, 10] . Other multiple therapies include a non-antimalarial medicine to enhance the antimalarial effect of a blood schizontocidal drug, such as the combination of CQ and chlorpheniramine (CP). However, the major disadvantage of combination treatments is the increased risk of adverse effects and increased cost of treatment.
Optimal controls have vastly been used in determining control strategies of disease dynamics, especially in the control of human immunodeficiency virus and tuberculosis [1, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . In these studies, optimal control therapy strategies were explored using Pontryagin's maximum principle using dynamical models. However, up-to date, to the best of our knowledge no work has been done to seek optimal control schemes for malaria drugs despite frantic efforts to find effective treatment and vaccine schemes. Emergence of P. falciparum resistance to widely used antimalarial drugs such as CQ has made treat-ment and control difficult. Therefore, the main thrust of this study is to determine how CQ treatment in combination with CP (or an malaria drug that reduce reproduction of merozoites in parasitised erythocytes) should be initiated, investigate drug percentage usage, and effective treatment in the face of emerging malaria drug resistant strains with aid of a model that incorporates the cellular and humoral immune response mechanisms in an elaborate way. This paper is organised as follows, in Section 2 we present a basic malaria model [24] . We incorporate malaria drug administration in Section 3 and develop the objective functional to determine an optimal control strategy in the treatment of malaria. Existence and characterisation of the optimal control are carried out in Section 4 and 5, respectively. The optimality system and its proof are given in Section 6. In Section 7 we present the numerical simulations of the optimal system and concluding remarks are provided in Section 8.
Malaria intra-host model
Here we present a malaria model proposed by Chiyaka et al. [24] , which models the interaction of (i) uninfected red blood cells (X), (ii) infected red blood cells (Y ), (iii) immune cells (B), (iv) merozoites (M ), and (v) antibodies (A). Red blood cells are recruited naturally at a constant rate such that their natural turn over is λx µx and are further recruited at a rate σ in response to the population of infected red blood cells, which is induced by infected red blood cells. Red blood cells are infected by merozoites at a rate β and infected cells die or burst at rate u y . Bursting of infected cells release r daughter merozoites per infected cells. Infection of red blood cells is counteracted by parasite specific antibodies, such that the increase of antibodies result in the reduction of infected cells. This effect is represented by the term, ( , and more immune cells proliferate at the site of infection in proportion to the density of infected red blood cells and merozoites at rates p y and p m with proliferation saturation limits of K 0 and K 1 , respectively. Antibodies are secreted at rate η, this secretion is induced by immune cells and depends on the density of merozoites in the blood, that is as the population of merozoites increase more antibodies will be secreted. Merozoite specific antibodies decay at a rate µ A . These assumptions lead to the following system of equations:
Interested readers may refer to [24] for the mathematical properties of model.
Treatment of malaria with antimalarial drugs
The administration of malaria drug, CQ, interact with parasitized erythrocytes. The drug diffuses into parasite lysosomal and becomes protonated in the acidic environment. It raises the pH of lysosome, inhibiting the polymerase that converts toxic free haem to a harmless by-product. It makes the survival and development of parasite difficult by preventing its digestion of haemoglobin and by reducing its supply of amino acids. Since CQ-resistant P. falciparum strains are rampant in sub-Saharan Africa we consider the administration of CQ in combination with CP to enhance CQ to suppress merozoites reproduction in erythrocytes. Therefore administration of CQ in combination with CP reduces the burst size r of infected red blood cells to (1 − γ(t))r, where γ(t) is the normalised CQ and CP dosage as a function of time.
We define our objective functional as
The first term represents the benefit of immune cells. The parameters G 1 and G 2 represent the weight constants on the benefit and cost on the merozoite population and the control, respectively. Our goal is to maximise the benefit based on the number of immune cells and treatment while minimising the merozoite population and the systemic cost (adverse effects and cost of treatment) of drug chemotherapy. The value γ(t) = 1 represents maximal use of chemotherapy and the maximal cost is represented by γ(t) 2 . We therefore seek an optimal control γ * such that
The basis framework of this problem is to characterise the optimal control and prove the existence of the optimal control and uniqueness of the optimality system.
Existence of an optimal control
The existence of an optimal control is proved by a result from Fleming and Rishel [25] .
The boundedness of solutions of system of Eqs. (6)- (10) for a finite time interval is used to prove the existence of an optimal control. For biological relevance of the model we impose restrictions that the growth of X(t) and B(t) is bounded, therefore we use X(t) < X max and B(t) < B max , where X max and B max are the maximum numbers of RBCs and immune cells, respectively. The upper bounds of the solutions of the system of Eqs. (6)- (10) are determined.
Note: (i) the upper bound of Y * is obtained when A * = A min , where 0 ≤ A min ≤ A * , (ii) the most positive value of M * is obtained with B min , (0 ≤ B min < B max ) and its worth noting that 0 ≤ ( M * K1+M * ) < 1. Therefore, the supersolutions Y * , M * , and A * are bounded on a finite time interval.
To determine existence of an optimal control to our problem, we use a result from [25, Thm. 4.1, pp. 68-69], where the following properties must be satisfied:
1. The set of controls and corresponding state variables is nonempty.
2. The control set U is convex and closed. 
2 , is Lebesque integrable and concave on U. Furthermore, c 1 , c 2 > 0 and κ > 1, hence satisfying
therefore the optimal control exist, since the states are bounded.
Characterisation
Since there exists an optimal control for maximising the functional (11) subject to Eqs. (6)- (10), we use Pontryagin's maximum principle to derive the necessary conditions for this optimal control. The Lagrangian is defined as,
where w 1 (t) ≥ 0, w 2 (t) ≥ 0 are penalty multipliers satisfying w 1 (t)(b − γ(t)) = 0 and w 2 (t)(γ(t) − a) = 0 at the optimal γ * .
Theorem 1.
Given an optimal control γ * and solutions of the corresponding state system (6)- (10), there exist adjoint variables λ i , i = 1, . . . , 5, satisfying
transversality conditions λ i (t f ) = 0 for i = 1, . . . , 5.
Proof. The form of the adjoint equation and transversality conditions are standard results from Pontryagin's maximum principle [25, 27] ; therefore, solutions to the adjoint system exist and are bounded. To determine the interior maximum of our lagrangian, we take the partial derivate of L with respect to γ(t) and set it to zero. Thus,
Making γ(t) * subject of formulae
To determine an explicit expression for the control without w 1 (t) and w 2 (t), a standard optimality technique is utilized. The following three cases are considered to determine a specific characterisation of the optimal control.
(i) On the set {t|a < γ(t) * < b}, w 1 (t) = w 2 (t) = 0. Hence the optimal control is
(ii) On the set {t | a = γ(t) * }, w 1 (t) = 0, hence
this implies that
(iii) On the set {t | b = γ(t) * }, w 2 (t) = 0, hence
Combining these three cases, the optimal control is characterised as,
We consider the optimal system next.
The optimal system
The optimality system consists of the state system coupled with the adjoint system with the initial conditions, the transversality conditions and the characterisation of the optimal control.
With
Uniqueness of the optimality system
The state system and adjoint system have finite upper bounds. These bounds are needed in the uniqueness proof of the optimality system. 
Following the same procedure for the remaining state variables and adjoint variables, for Y andȲ , M andM , B andB, A andĀ the following equations are obtained.
These estimates utilize upper bounds on the solutions. They involve separating terms that involve squares, several multiplied terms, and quotients. Note:
This shows uniqueness and the combination of the integrals produces
Thus, from the expression (47), using the non-negativity of the variable expressions evaluated at the initial and the final time and simplifying, the inequality is reduced to 
The uniqueness for a small time interval is usual in "two-point" boundary value problems due to opposite time orientations; the state equations have initial conditions and the adjoint equations have final time conditions. The optimal control γ(t)
* are characterized in terms of the unique solution of the optimality system. The above optimal controls give an optimal treatment strategy for the malaria infected patient under treatment with CQ and CP.
Numerical simulations
The optimality system is solved using an iterative method with Runge-Kutta fourth order scheme coded in Matlab. Starting with a guess for the adjoint variables, the state equations are solved forward in time. Then those state values are used to solve the adjoint equations backward in time, and the iterations continue until convergence. We carry simulations to determine the impact of systemic costs and drug percentage usage on the treatment strategy. Simulations in Fig. 1 were aimed to find out the impact of a treatment scheme that has varying levels of merozoite population suppression with fixed systemic cost weights. The investigation (Fig. 2) also, aimed to explore a scheme with a fixed merozoite population suppression, which probe the effect of different systemic cost weights. And then to ascertain if initial disease conditions has a contributing factor in determing a treatment scheme. In Fig. 1 we fix the value of G 2 at 75.0 (the weight of the optimal control) and vary the weight of merozoites (G 1 ) from 1.25 to 12.5 in the objective functional. In Fig. 2 three values (75.0, 250.0, and 750.0) of G 2 are used while the value of G 1 is fixed at 2.5 and in Fig. 3 three initial values (150.0, 300.0, and 450.0) of immune cells (B) are used with G 1 and G 2 fixed at 1.25 and 75.0, respectively. In Fig. 1 , increasing G 1 from 1.25 to 12.5 achieves maximal drug administration close to 10 days with out early withdrawal of therapy, while when the value G 1 is equivalent to 1.25, therapy is continuous within the first 8 days after which therapy is tapped off. Increasing the value of G 1 implies increasing the minimisation of merozoites in the objective functional. This effect is accompanied by reduction in infected red blood cells and merozoites while red blood cells are boosted. Contrary, fixing G 1 and increasing G 2 (in Fig. 2) , that is increasing treatment systemic costs of malarial drugs or if the adverse effects are increased forces treatment to be withdrawn early. The effects of increasing the weight G 2 are counteracted by increasing G 1 , hence suggesting that a therapy with high systemic costs combined with the high potential to suppress merozoites could be administered for a longer time. This has more benefits than a strategy with high systemic costs but with low suppression of merozoites. Fig. 3 suggests that starting with different amounts of immune cells does not significantly affect treatment schedule, drug percentage usage and treatment interval but affect levels of red blood cells (infected and uninfected) and merozoites. It is expected that as immune cells are increased then merozoites will be reduced, but here, results suggest that as the immune cells are increased only the levels of antibodies are increased, this propels the reduction of infected red blood cells. However, the rate of recovery of uninfected red blood cells is slow as well as the clearance of merozoites.
This study suggests that a malarial therapy that seeks to minimise merozoites population with less side effects is more beneficial to patients. Also a treatment scheme with high systemic costs but with high suppression of merozoite reproduction has the potential to give positive treatment results since high merozoite suppression seems to compensate for high systemic costs. However, a treatment scheme that seeks to maximise the immune cells does not significantly improve the treatment of malaria.
Conclusion
Recently, optimal control studies [31, 32] addressed optimal control strategies of malaria in a population. Okosun et al. [32] derived conditions under which it is optimal to eradicate the disease and examine the impact of a possible combined vaccination and treatment strategies on the disease transmission. The study [31] , predicated factors that are critical in the transmission of malaria in a population (the contact rate and the bitting rate). Their optimal scheme expored the effectiveness of spraying of insecticides in a population and the contribution of immigrants to the spread of malaria. They showed that immigrants have no significant contribution to the spread of the disease.
In this study, we used techniques and ideas of optimal control to design malaria treatment therapy protocols in the human body, unlike in the rest of the studies that looked at malaria transmission and treatment in a human population. We presented a malaria immune model and then constructed an optimal problem with an objective to maximise immune cell benefits and minimise the merozoite population and treatment systemic costs. We derived optimal treatment schemes by solving the optimality system. Results in this study suggest that administration of malarial drugs with less adverse effects and high suppression of merozoites or administration of malaria therapy with high systemic costs and high suppression of merozoites might be beneficial to malaria patients.
